Discover and read the best of Twitter Threads about #sabcs21

Most recents (3)

1) Welcome to our THIRD #accredited serialized #tweetorial from @onc_ce, your new (and only) home for the latest education from #experts on #cancer care. #Physicians #nurses #pharmacists #PAs and #NPs can all earn 0.5h CE/#CME by following this thread!
2) We continue to highlight the San Antonio Breast Cancer Symposium (#SABCS21), with more expert commentary for OUR #tweetorial followers! Our content authority is Hal Burstein MD (@drhburstein) from @DanaFarber Cancer Institute & @HarvardMed.
3) @Onc_ce and its companion website are supported by educational grants from Astra Zeneca and Daiichi Sankyo and content is intended for #healthcare providers. Faculty disclosures are listed at
Read 35 tweets
1/14 🆕 🚨Accelerated article on #breastcancer just out in @nature! #bcsm

We asked:
1️⃣ What drives response to #chemotherapy in #breast #cancer
2️⃣ Can we use #machinelearning to predict response to chemotherapy❓


A 🧵👇👇👇 @OncoAlert
2/14 We are unable to #predict #response to treatment in clinic…

✅Good response ➡️treatment very effective ➡️better survival
❌Poorer response ➡️treatment less effective ➡️worse survival

Being able to forecast response would be a landmark advance!
3/14 We ran a study in women with #breastcancer @CUH_NHS+@CRUK_CI:
1️⃣who had a #cancer biopsy (which we analysed)
2️⃣received 18 weeks of chemo+/-targeted therapy
3️⃣had surgery (and we measured how much cancer remained)

We associated PRE-therapy profiles↔️POST-therapy response👇
Read 14 tweets
$OLMA San Antonio abstracts released tomorrow AM, so here’s a brief thread on expectations and how to contextualize the data #SABCS21

What does @OlemaOncology OP-1250 need to score in their Ph1 ER+/HER2 in mBC?
$OLMA Cross-trial of Ph1 SERDs have a wide range of ORRs ranging from 0 - 20%, but that alone doesn’t reflect how SOC has changed over time (ie. use of CDK4/6) or safety trade-offs
See $ARVN chart showing background use of Palbo and co. moving earlier in the treatment paradigm Image
On $ARVN: 471 has been cited by sell-side/mgmt as OP-1250 benchmark

Yee wrongly notes a 21% ORR (+no DoR) - should be 7%; ARVN mgmt has told investors that both uPRs had new lesions before confirmation = SD

So a $1B u/f $PFE deal (up to $2.4B) for 7% ORR and clean safety Image
Read 13 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!